Mirum's brelovitug meets Phase 2b primary endpoint in chronic HDV; 100% virologic response at 300 mg QW

Mirum Pharmaceuticals, Inc.

100% of patients on 300 mg QW and 75% on 900 mg Q4W achieved virologic response vs 0% control.
Primary composite endpoint (virologic response + ALT normalization) reached by 45% and 35% vs 0% control (p=0.003, 0.024).
Brelovitug was well tolerated; no discontinuations, low grade 3+ events, no related serious AEs.
Full Phase 2b results to be presented at EASL Congress May 27-30, 2026.
Phase 3 topline data from AZURE-1/4 expected H2 2026; potential U.S. BLA submission in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.